Saol Therapeutics Announces FDA Approval of LYVISPAH™

/PRNewswire/ -- Saol Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved Saol's LYVISPAH™ (baclofen) oral granules....

Related Keywords

New York , United States , Ireland , Kaaghaz , Khorasane Ra Avi , Iran , Dublin , Bermuda , David Penake , Michael Saulino , Cooper University Hospital , Drug Administration , Saol Therapeutics , Physical Medicine , Cytomegalovirus Immune Globulin Intravenous , Immune Globulin Intravenous , Pyruvate Dehydrogenase Complex Disorder , Chronic Pain , Sclerosis Prevalence , Demos Medical , Globulin Intravenous , Hepatitisb Immune Globulin , Health Care Amp Hospitals , Medical Equipment , Medical Pharmaceuticals , Fda Approval ,